Review Board

Editors

  • Gill Bates, King’s College London, UK
  • Mike Levine, University of California, Los Angeles, USA
  • Sarah Tabrizi, University College London, UK

Board of Reviewers

  • Neil Aronin, University of Massachusetts Medical School, USA
  • Elizabeth Aylward, Seattle Children’s Research Institute, USA
  • Roger Barker, University of Cambridge, UK
  • Anna Rita Bentivoglio, Universita Cattolica del Sacro Cuore, Italy
  • Kevin Biglan, University of Rochester Medical Center, USA
  • Maria Björkqvist, Lund University, Sweden
  • Jean-Marc Burgunder, Universities of Bern, Switzerland and Chengdu, China
  • Monica Busse, Cardiff University, UK
  • Marie-Francoise Chesselet, University of California, Los Angeles, USA
  • David Craufurd, University of Manchester, UK
  • Beverly Davidson, University of Iowa, USA
  • Stefano Di Donato, Istituto Neurologico Carlo Besta, Italy
  • Marian DiFiglia, Massachusetts General Hospital, USA
  • Steve Dunnett, Cardiff University, UK
  • Alexandra Durr,Université Pierre et Marie Curie, France
  • Lisa Ellerby, Buck Institute, USA
  • Kenneth Evans, Ontario Cancer Biomarker Network, Canada
  • Joaquim Ferreira, Lisbon School of Medicine, Portugal
  • Flaviano Giorgini, University of Leicester, UK
  • Steven Hersch, Massachusetts General Hospital, USA
  • Aileen Ho, University of Reading, UK
  • Nicola Hobbs, University College London, UK
  • Peter Holmans, Cardiff University, UK
  • David Housman,Massachusetts Institute of Technology, USA
  • Bob Hughes, Buck Institute, USA
  • Carl Johnson, Hereditary Disease Foundation, USA
  • Lesley Jones, Cardiff University, UK
  • Jan Kassubek, University of Ulm, Germany
  • Alex Kazantsev, Harvard Medical School, USA
  • Stefan Kloppel, University Hospital Freiburg, Germany
  • Berry Kremer, University Medical Center Groningen, Netherlands
  • Blair Leavitt, University of British Columbia, Canada
  • Xiao-Jiang Li, Emory University, USA
  • Ruth Luthi-Carter, Ecole Polytechnique Fédérale de Lausanne, Switzerland
  • Clement Loy, University of Sydney and Westmead Hospital, Australia
  • Jenny Morton, University of Cambridge, UK
  • Paul Muchowski, University of California, San Francisco, USA
  • Martha Nance, Struthers Parkinson’s Center, MN, USA
  • Christian Neri, INSERM, France
  • Jørgen E. Nielsen, Copenhagen University Hospital, Denmark
  • Hoa Nguyen, Universität Tübingen, Germany
  • Peggy Nopoulos, University of Iowa, USA
  • Oliver Quarrell, Sheffield Children’s Hospital, UK
  • Lynn Raymond, University of British Columbia, Canada
  • Ralf Reilmann, University of Münster, Germany
  • Eric Reits, University of Amsterdam, Netherlands
  • Hugh Rickards, Birmingham and Solihull Mental Health NHS Foundation Trust, UK
  • Raymund Roos, Leiden University Medical Center, Netherlands
  • Christopher Ross, Johns Hopkins University, USA
  • Anne Rosser, Cardiff University, UK
  • Rachael Scahill, University College London, UK
  • Julie Stout, Monash University, Australia
  • Ray Truant, McMaster University, Canada
  • William Yang, University of California, Los Angeles, USA
  • Erich Wanker,Max Delbrück Center for Molecular Medicine Berlin, Germany
  • Vanessa Wheeler, Massachusetts General Hospital, USA
  • Edward Wild, University College London, UK
Consulting Editor for PLOS
  • Elizabeth Silva, Associate Editor, PLOS ONE

Funding and competing interests statements

PLOS Currents: Huntington Disease is produced with support from CHDI Foundation. Editorial responsibility for the content in PLOS Currents: Huntington Disease rests entirely with PLOS and the Editors.

  • Gill Bates has received funding from: CHDI Foundation; MRC; Wellcome Trust; Huntington’s Disease Society of America; European Union FP7 framework; and the Huntington’s Disease Association UK. She is on the MRC Neuroscience and Mental Health Board; Co-chair of the Executive Committee of the European Huntington’s Disease Network; and on the Medical Advisory Panel of the UK Huntington’s Disease Association. King’s College London licenses the R6/2 mouse model of HD (constructed in the Bates lab) for commercial work.
  • Michael S. Levine has received funding from multiple grants from the National Institutes of health, specifically the National Institute of Neurological Disorders and Stroke, and contracts with the CHDI. He also serves on the Scientific Advisory Board of the Hereditary Disease Foundation.
  • Sarah Tabrizi has received funding from the Medical Research Council (MRC), the Wellcome Trust, the European Union FP7 framework, UK Dementia and Neurodegenerative disease network, European Huntington’s Disease Network, and CHDI. She is on the medical advisory panel of the UK patient Huntington’s disease association. She has done consultancy work for Alynlam/Medtronic and Siena Biotech.